GSK deals cell therapy another setback
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
Sanofi’s oncology hopes crumble
The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.
No place for Wee1 in Astra’s synthetic lethality work
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
